Epigenetic Mechanisms of Neurodegeneration in Huntington’s Disease

Epigenetic regulation of cholinergic receptor M1 (CHRM1) by histone H3K9me3 impairs Ca2+ signaling in Huntington’s disease

(2013) Junghee Lee et al.   ACTA NEUROPATHOLOGICA

A novel method for detecting 7-methyl guanine reveals aberrant methylation levels in Huntington disease

(2013) Beena Thomas et al.   ANALYTICAL BIOCHEMISTRY

Altered DNA methylation and RNA splicing could be key mechanisms in Huntington disease

(2013) Heather Wood   Nature Reviews Neurology

Increased 5-Methylcytosine and Decreased 5-Hydroxymethylcytosine Levels are Associated with Reduced Striatal A2AR Levels in Huntington’s Disease

(2013) Izaskun Villar-Menéndez et al.   NEUROMOLECULAR MEDICINE

Extensive changes in DNA methylation are associated with expression of mutant huntingtin

(2013) C. W. Ng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression

(2012) Dongbo Yu et al.   CELL

Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin–proteasomal and autophagy systems

(2012) Haiqun Jia et al.   HUMAN MOLECULAR GENETICS

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease

(2012) Haiqun Jia et al.   NEUROBIOLOGY OF DISEASE

Genome-Wide Histone Acetylation Is Altered in a Transgenic Mouse Model of Huntington's Disease

(2012) Karen N. McFarland et al.   PLoS One

New insights into non-coding RNA networks in Huntington's disease

(2011) Noel J. Buckley et al.   EXPERIMENTAL NEUROLOGY

Using non-coding small RNAs to develop therapies for Huntington's disease

(2011) Y Zhang et al.   GENE THERAPY

Regulation of miR-146a by RelA/NFkB and p53 in STHdhQ111/HdhQ111 Cells, a Cell Model of Huntington's Disease

(2011) Jayeeta Ghose et al.   PLoS One

SAHA Decreases HDAC 2 and 4 Levels In Vivo and Improves Molecular Phenotypes in the R6/2 Mouse Model of Huntington's Disease

(2011) Michal Mielcarek et al.   PLoS One

Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse

(2011) Y. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/electrochemical array/mass spectrometry and off-line tandem mass spectrometry

(2010) Erika N. Ebbel et al.   ANALYTICAL BIOCHEMISTRY

Altered microRNA regulation in Huntington's disease models

(2010) Soon-Tae Lee et al.   EXPERIMENTAL NEUROLOGY

Epigenetic regulation in the pathophysiology of Alzheimer's disease

(2010) Leonidas Chouliaras et al.   PROGRESS IN NEUROBIOLOGY

Sustained effects of nonallele-specificHuntingtinsilencing

(2009) Valérie Drouet et al.   ANNALS OF NEUROLOGY

Posttranscriptional Crossregulation between Drosha and DGCR8

(2009) Jinju Han et al.   CELL

A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference

(2009) Maria Stella Lombardi et al.   EXPERIMENTAL NEUROLOGY

Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice

(2009) Ryan L Boudreau et al.   MOLECULAR THERAPY

Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs

(2009) Jiaxin Hu et al.   NATURE BIOTECHNOLOGY

Monoallele deletion of CBP leads to pericentromeric heterochromatin condensation through ESET expression and histone H3 (K9) methylation

(2008) Junghee Lee et al.   HUMAN MOLECULAR GENETICS

AAV Vector–mediated RNAi of Mutant Huntingtin Expression Is Neuroprotective in a Novel Genetic Rat Model of Huntington's Disease

(2008) Nicholas R Franich et al.   MOLECULAR THERAPY

DNA methylation landscapes: provocative insights from epigenomics

(2008) Miho M. Suzuki et al.   NATURE REVIEWS GENETICS

Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi

(2008) J. L. McBride et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice

(2008) E. A. Thomas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A microRNA-based gene dysregulation pathway in Huntington's disease

(2007) Rory Johnson et al.   NEUROBIOLOGY OF DISEASE